Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- National Cancer Institute: Surveillance E, and End Results Program. Cancer stat facts: pancreatic cancer 2020.(Available at:) (Accessed May 23, 2020)
- Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.JAMA. 2013; 310: 1473-1481
- Cancer statistics, 2021.CA Cancer J Clin. 2021; 71: 7-33
- Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.Arch Surg. 1985; 120: 899-903
- Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study.Eur J Cancer. 1993; 29A: 698-703
- A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.N Engl J Med. 2004; 350: 1200-1210
- Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.JAMA. 2007; 297: 267-277
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol. 1997; 15: 2403-2413
- Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.JAMA. 2010; 304: 1073-1081
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).Lancet. 2016; 388: 248-257
- ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.J Clin Oncol. 2016; 34 (abstr LBA4006)
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med. 2013; 369: 1691-1703
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med. 2011; 364: 1817-1825
- FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.N Engl J Med. 2018; 379: 2395-2406
- Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2016; 34: 2541-2556
- Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group.Cancer. 1987; 59: 2006-2010
- Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.Ann Surg. 1999; 230 ([discussion: 782–4]): 776-782
- Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.JAMA. 2008; 299: 1019-1026
- Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data.Cancer. 2007; 110: 2191-2201
- Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits?.J Am Coll Surg. 2009; 208 ([discussion: 838–41]): 829-838
- A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.Ann Surg Oncol. 2006; 13: 150-158
- Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.J Clin Oncol. 2008; 26: 3496-3502
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Cancer. 2013; 119: 2692-2700
- Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response.Eur J Surg Oncol. 2010; 36: 987-992
- A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.Ann Surg. 2014; 260: 142-148
- Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.Ann Surg. 2014; 260: 372-377
- Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.J Clin Oncol. 2014; 32: 504-512
- Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.Cancer. 2016; 122: 2979-2987
- Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis.Pancreas. 2013; 42: 249-253
- Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.J Am Coll Surg. 2014; 219: 111-120
- Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.Surgery. 2015; 158: 1545-1555
- Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.Ann Surg. 1995; 221 ([discussion: 731–3]): 721-731
- Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.Lancet. 2001; 358: 1576-1585
- Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.Ann Surg. 2007; 246: 52-60
- NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.Surgery. 2011; 149: 311-320
- Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101.JAMA Surg. 2016; 151: e161137
- Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.Arch Surg. 1992; 127: 1335-1339
- Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study.Cancer. 1993; 72: 2124-2133
- Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.J Clin Oncol. 1997; 15: 928-937
- Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.J Clin Oncol. 2008; 26: 2526-2531
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.Lancet. 2017; 389: 1011-1024
- FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.Oncologist. 2013; 18: 543-548
- Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.Ann Surg Oncol. 2015; 22: 1153-1159
- Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC Trial.J Clin Oncol. 2020; 38: 1763-1773
- Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.World J Gastroenterol. 2014; 20: 15564-15579
- Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.PLoS Med. 2010; 7: e1000267
- Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.Br J Surg. 2018; 105: 946-958
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: pancreatic adenocarcinoma 2020.(Available at:) (Accessed May 23, 2020)
- Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial.JAMA Oncol. 2021; 7: 421-427
- Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma.Ann Surg. 2020; 272: 481-486
- Prognostic factors of survival after neoadjuvant treatment and resection for initially unresectable pancreatic cancer.Ann Surg. 2019; 273: 154-162
- Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial.Ann Surg. 2018; 268: 215-222
- Comment on "Interpreting clinical benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer (BRPC).Ann Surg. 2019; 270: e48-e50
- Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial.JAMA Oncol. 2018; 4: 963-969
- Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.BMC Cancer. 2017; 17: 505
- Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.J Clin Oncol. 2021; 39: 377
- Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer.Am J Clin Oncol. 2019; 42: 247-252
- NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.World J Surg. 2011; 35: 1580-1589
Article info
Publication history
Published online: April 07, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
